Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations
This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.
Gespeichert in:
| Veröffentlicht in: | Clinical and applied thrombosis/hemostasis 2003-10, Vol.9 (4), p.293-297 |
|---|---|
| Hauptverfasser: | , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 297 |
|---|---|
| container_issue | 4 |
| container_start_page | 293 |
| container_title | Clinical and applied thrombosis/hemostasis |
| container_volume | 9 |
| creator | Leong, Wendy Hoppensteadt, Debra A. |
| description | This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies. |
| doi_str_mv | 10.1177/107602960300900404 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_AFRWT</sourceid><recordid>TN_cdi_proquest_miscellaneous_71431163</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sage_id>10.1177_107602960300900404</sage_id><sourcerecordid>2344182571</sourcerecordid><originalsourceid>FETCH-LOGICAL-c411t-568e5e5b755fa9a4a4968b2452b7e04907dd5e1d638178d7d7ca990e89e3b89b3</originalsourceid><addsrcrecordid>eNp90E1LxDAQBuAgih-rf8CDFARv1Uzz7U0W3RV2UVDxWNJ2qpG2WZMW8d9b2QVBwVPm8Mw74SXkGOg5gFIXQJWkmZGUUWoo5ZRvkX0wTKeZytj2OI8g_RZ75CDGN0rBSCN3yR5wKRhnep8sZ9hhcGVy40MbE18nC_-RLn2D5dDYkD6je3ntkzmubHBdvEwefIvJfbBl70rbJFPfRVdhsL0bp0OyU9sm4tHmnZCnm-vH6Txd3M1up1eLtOQAfSqkRoGiUELU1lhuuZG6yLjICoWUG6qqSiBUkmlQulKVKq0xFLVBVmhTsAk5W-eugn8fMPZ562KJTWM79EPMFXAGINkIT3_BNz-EbvxbnjHOQWdCwaiytSqDjzFgna-Ca234zIHm31Xnf6sel0420UPRYvWzsul2BBdrEO0L_tz9J_ILa9aEfw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2344182571</pqid></control><display><type>article</type><title>Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations</title><source>Sage Journals GOLD Open Access 2024</source><creator>Leong, Wendy ; Hoppensteadt, Debra A.</creator><creatorcontrib>Leong, Wendy ; Hoppensteadt, Debra A.</creatorcontrib><description>This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.</description><identifier>ISSN: 1076-0296</identifier><identifier>EISSN: 1938-2723</identifier><identifier>DOI: 10.1177/107602960300900404</identifier><identifier>PMID: 14653438</identifier><language>eng</language><publisher>Thousand Oaks, CA: SAGE Publications</publisher><subject>Anticoagulants ; Anticoagulants - standards ; Drug Approval ; Drugs, Generic - standards ; Heparin, Low-Molecular-Weight - standards ; Humans</subject><ispartof>Clinical and applied thrombosis/hemostasis, 2003-10, Vol.9 (4), p.293-297</ispartof><rights>Copyright SAGE PUBLICATIONS, INC. Oct 2003</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c411t-568e5e5b755fa9a4a4968b2452b7e04907dd5e1d638178d7d7ca990e89e3b89b3</citedby><cites>FETCH-LOGICAL-c411t-568e5e5b755fa9a4a4968b2452b7e04907dd5e1d638178d7d7ca990e89e3b89b3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://journals.sagepub.com/doi/pdf/10.1177/107602960300900404$$EPDF$$P50$$Gsage$$H</linktopdf><linktohtml>$$Uhttps://journals.sagepub.com/doi/10.1177/107602960300900404$$EHTML$$P50$$Gsage$$H</linktohtml><link.rule.ids>314,780,784,21966,27853,27924,27925,44945,45333</link.rule.ids><linktorsrc>$$Uhttps://journals.sagepub.com/doi/full/10.1177/107602960300900404?utm_source=summon&utm_medium=discovery-provider$$EView_record_in_SAGE_Publications$$FView_record_in_$$GSAGE_Publications</linktorsrc><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/14653438$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Leong, Wendy</creatorcontrib><creatorcontrib>Hoppensteadt, Debra A.</creatorcontrib><title>Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations</title><title>Clinical and applied thrombosis/hemostasis</title><addtitle>Clin Appl Thromb Hemost</addtitle><description>This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.</description><subject>Anticoagulants</subject><subject>Anticoagulants - standards</subject><subject>Drug Approval</subject><subject>Drugs, Generic - standards</subject><subject>Heparin, Low-Molecular-Weight - standards</subject><subject>Humans</subject><issn>1076-0296</issn><issn>1938-2723</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2003</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNp90E1LxDAQBuAgih-rf8CDFARv1Uzz7U0W3RV2UVDxWNJ2qpG2WZMW8d9b2QVBwVPm8Mw74SXkGOg5gFIXQJWkmZGUUWoo5ZRvkX0wTKeZytj2OI8g_RZ75CDGN0rBSCN3yR5wKRhnep8sZ9hhcGVy40MbE18nC_-RLn2D5dDYkD6je3ntkzmubHBdvEwefIvJfbBl70rbJFPfRVdhsL0bp0OyU9sm4tHmnZCnm-vH6Txd3M1up1eLtOQAfSqkRoGiUELU1lhuuZG6yLjICoWUG6qqSiBUkmlQulKVKq0xFLVBVmhTsAk5W-eugn8fMPZ562KJTWM79EPMFXAGINkIT3_BNz-EbvxbnjHOQWdCwaiytSqDjzFgna-Ca234zIHm31Xnf6sel0420UPRYvWzsul2BBdrEO0L_tz9J_ILa9aEfw</recordid><startdate>20031001</startdate><enddate>20031001</enddate><creator>Leong, Wendy</creator><creator>Hoppensteadt, Debra A.</creator><general>SAGE Publications</general><general>SAGE PUBLICATIONS, INC</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope></search><sort><creationdate>20031001</creationdate><title>Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations</title><author>Leong, Wendy ; Hoppensteadt, Debra A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c411t-568e5e5b755fa9a4a4968b2452b7e04907dd5e1d638178d7d7ca990e89e3b89b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2003</creationdate><topic>Anticoagulants</topic><topic>Anticoagulants - standards</topic><topic>Drug Approval</topic><topic>Drugs, Generic - standards</topic><topic>Heparin, Low-Molecular-Weight - standards</topic><topic>Humans</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Leong, Wendy</creatorcontrib><creatorcontrib>Hoppensteadt, Debra A.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><jtitle>Clinical and applied thrombosis/hemostasis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Leong, Wendy</au><au>Hoppensteadt, Debra A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations</atitle><jtitle>Clinical and applied thrombosis/hemostasis</jtitle><addtitle>Clin Appl Thromb Hemost</addtitle><date>2003-10-01</date><risdate>2003</risdate><volume>9</volume><issue>4</issue><spage>293</spage><epage>297</epage><pages>293-297</pages><issn>1076-0296</issn><eissn>1938-2723</eissn><abstract>This commentary briefly reviews the controversies of therapeutic and generic interchangeability, as they apply to the antithrombotic drug class called low-molecular-weight heparin (LMWH). Recommendations are prepared for the generic LMWH approval process by various regulatory bodies.</abstract><cop>Thousand Oaks, CA</cop><pub>SAGE Publications</pub><pmid>14653438</pmid><doi>10.1177/107602960300900404</doi><tpages>5</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | ISSN: 1076-0296 |
| ispartof | Clinical and applied thrombosis/hemostasis, 2003-10, Vol.9 (4), p.293-297 |
| issn | 1076-0296 1938-2723 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_71431163 |
| source | Sage Journals GOLD Open Access 2024 |
| subjects | Anticoagulants Anticoagulants - standards Drug Approval Drugs, Generic - standards Heparin, Low-Molecular-Weight - standards Humans |
| title | Generic Forms of Low-Molecular-Weight Heparins: Some Practical Considerations |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A06%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_AFRWT&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Generic%20Forms%20of%20Low-Molecular-Weight%20Heparins:%20Some%20Practical%20Considerations&rft.jtitle=Clinical%20and%20applied%20thrombosis/hemostasis&rft.au=Leong,%20Wendy&rft.date=2003-10-01&rft.volume=9&rft.issue=4&rft.spage=293&rft.epage=297&rft.pages=293-297&rft.issn=1076-0296&rft.eissn=1938-2723&rft_id=info:doi/10.1177/107602960300900404&rft_dat=%3Cproquest_AFRWT%3E2344182571%3C/proquest_AFRWT%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2344182571&rft_id=info:pmid/14653438&rft_sage_id=10.1177_107602960300900404&rfr_iscdi=true |